/
MBX
$53.85+$1.54 (+2.94%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.5B
48M shares
52-week range
$9.63 – $55.00
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$30.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $248.0K |
| Gross profit | $0 | $0 | $0 | −$248.0K |
| Gross margin | — | — | — | — |
| R&D | $21.4M | $28.5M | $57.4M | $79.2M |
| Operating income | −$25.2M | −$35.3M | −$68.2M | −$98.1M |
| EBITDA | −$25.7M | −$32.4M | −$61.7M | −$86.7M |
| Net income | −$26.1M | −$32.6M | −$61.9M | −$87.0M |
| Net margin | — | — | — | — |
| EPS (diluted) | -0.82 | -1.02 | -1.85 | -2.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.81 | $-3.18–$-2.62 | 8 |
| 2027 | $0 | $-3.89 | $-4.24–$-3.35 | 8 |
| 2028 | $24M | $-4.12 | $-5.24–$-1.59 | 7 |
| 2029 | $130M | $-2.93 | $-2.93–$-2.93 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.02
Price
$53.85
Implied downside
-96%
Peer comparison
MBX Biosciences, Inc. Common Stock
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
www.mbxbio.com- Employees
- 63
- IPO / List date
- Sep 13, 2024
- HQ
- CARMEL, IN
Held by traders on TradeandTell
No one on the platform currently holds MBX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 32,644 | $1.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MBX yet.
